Monoclonal Antibodies Market - Forecasts from 2025 to 2030
Description
The Monoclonal Antibodies Market is expected to grow from US$201.429 billion in 2025 to US$340.700 billion in 2030, at a CAGR of 11.08%.
The immune system naturally produces antibodies in response to an infection. A monoclonal antibody is a molecule designed to enhance the body’s natural immune system response against an invader, such as cancer or an infection. It is developed in a laboratory and hence comes under man-made drugs. Monoclonal antibodies are created to specifically target an essential part of the infectious process, and therefore, they have an advantage over other types of treatment for infections. It is created by exposing a white blood cell to a particular viral protein. It is then cloned to mass-produce antibodies, which target that virus. The monoclonal antibodies are developed to treat several viral infections, such as Ebola and rabies. They were widely used during the COVID-19 pandemic, as the clinical trials proved that the antibodies are effective in reducing the severity.
Monoclonal Antibodies Market Growth Drivers:
Increased demand for monoclonal antibodies
According to the World Health Organization, around 10 million people died due to cancer worldwide in 2020. For cancer treatment, monoclonal antibodies are significantly helpful, therefore, there is an increasing need for affordable cancer therapies. Moreover, during the COVID-19 pandemic, many monoclonal antibodies’ clinical trials took place in order to develop novel drug therapy, as well as a wide range of product approvals were made for emergency use in COVID-19 treatment.
With its growing demand, the market players have a strong focus on the development as well as the discovery of monoclonal antibody therapeutics. The step has been taken to offer highly specific treatment for complex and severe diseases. Furthermore, it will stimulate the monoclonal antibodies market growth potential.
Monoclonal Antibodies Market Geographical Outlook:
North America is expected to hold a significant market share during the anticipated period
North American countries have a well-developed healthcare infrastructure. However, the high intake of alcohol and junk/fast food culture in this region is leading to obesity and putting the population at a high risk of being infected with cancer.
Furthermore, new vaccines/drugs are being developed to help in the treatment of cancer patients. Amneal Pharmaceuticals announced the launch of bevacizumab-maly (Alymsys) in the United States. The drug is a biosimilar reference of bevacizumab (Avastin, Genentech). Bevacizumab-maly is developed by mAbxience. The drug will be useful in the treatment of metastatic colorectal cancer, first-line non-squamous non-small cell lung cancer, persistent, recurrent, or metastatic cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Monoclonal Antibodies Market Segmentation:
By Indication
Inflammatory Disease
Cancer
Microbial Disease
Others
By Source
Humanized
Human
Chimeric
Murine
By Application
Diagnostic
Therapeutic
Others
By End-User
Hospitals & Clinics
Research Laboratories
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
Japan
South Korea
India
Thailand
Taiwan
Others
The immune system naturally produces antibodies in response to an infection. A monoclonal antibody is a molecule designed to enhance the body’s natural immune system response against an invader, such as cancer or an infection. It is developed in a laboratory and hence comes under man-made drugs. Monoclonal antibodies are created to specifically target an essential part of the infectious process, and therefore, they have an advantage over other types of treatment for infections. It is created by exposing a white blood cell to a particular viral protein. It is then cloned to mass-produce antibodies, which target that virus. The monoclonal antibodies are developed to treat several viral infections, such as Ebola and rabies. They were widely used during the COVID-19 pandemic, as the clinical trials proved that the antibodies are effective in reducing the severity.
Monoclonal Antibodies Market Growth Drivers:
Increased demand for monoclonal antibodies
According to the World Health Organization, around 10 million people died due to cancer worldwide in 2020. For cancer treatment, monoclonal antibodies are significantly helpful, therefore, there is an increasing need for affordable cancer therapies. Moreover, during the COVID-19 pandemic, many monoclonal antibodies’ clinical trials took place in order to develop novel drug therapy, as well as a wide range of product approvals were made for emergency use in COVID-19 treatment.
With its growing demand, the market players have a strong focus on the development as well as the discovery of monoclonal antibody therapeutics. The step has been taken to offer highly specific treatment for complex and severe diseases. Furthermore, it will stimulate the monoclonal antibodies market growth potential.
Monoclonal Antibodies Market Geographical Outlook:
North America is expected to hold a significant market share during the anticipated period
North American countries have a well-developed healthcare infrastructure. However, the high intake of alcohol and junk/fast food culture in this region is leading to obesity and putting the population at a high risk of being infected with cancer.
Furthermore, new vaccines/drugs are being developed to help in the treatment of cancer patients. Amneal Pharmaceuticals announced the launch of bevacizumab-maly (Alymsys) in the United States. The drug is a biosimilar reference of bevacizumab (Avastin, Genentech). Bevacizumab-maly is developed by mAbxience. The drug will be useful in the treatment of metastatic colorectal cancer, first-line non-squamous non-small cell lung cancer, persistent, recurrent, or metastatic cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Monoclonal Antibodies Market Segmentation:
By Indication
Inflammatory Disease
Cancer
Microbial Disease
Others
By Source
Humanized
Human
Chimeric
Murine
By Application
Diagnostic
Therapeutic
Others
By End-User
Hospitals & Clinics
Research Laboratories
By Geography
North America
USA
Canada
Mexico
South America
Brazil
Argentina
Others
Europe
Germany
France
United Kingdom
Spain
Others
Middle East and Africa
Saudi Arabia
UAE
Others
Asia Pacific
China
Japan
South Korea
India
Thailand
Taiwan
Others
Table of Contents
142 Pages
- 1. INTRODUCTION
- 1.1. Market Overview
- 1.2. Market Definition
- 1.3. Market Segmentation
- 2. RESEARCH METHODOLOGY
- 2.1. Research Data
- 2.2. Assumptions
- 3. EXECUTIVE SUMMARY
- 3.1. Research Highlights
- 4. MARKET DYNAMICS
- 4.1. Market Drivers
- 4.2. Market Restraints
- 4.3. Porters Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
- 4.4. Industry Value Chain Analysis
- 5. MONOCLONAL ANTIBODY MARKET, BY INDICATION (2020-2030)
- 5.1. Introduction
- 5.2. Inflammatory Disease
- 5.3. Cancer
- 5.4. Microbial Disease
- 5.5. Others
- 6. MONOCLONAL ANTIBODY MARKET, BY SOURCE (2020-2030)
- 6.1. Introduction
- 6.2. Humanized
- 6.3. Human
- 6.4. Chimeric
- 6.5. Murine
- 7. MONOCLONAL ANTIBODY MARKET, BY APPLICATION (2020-2030)
- 7.1. Introduction
- 7.2. Diagnostic
- 7.3. Therapeutic
- 7.4. Others
- 8. MONOCLONAL ANTIBODY MARKET, BY END-USER (2020-2030)
- 8.1. Introduction
- 8.2. Hospitals & Clinic
- 8.3. Research Laboratories
- 9. MONOCLONAL ANTIBODY MARKET, BY GEOGRAPHY (2020-2030)
- 9.1. Introduction
- 9.2. North America
- 9.2.1. USA
- 9.2.2. Canada
- 9.2.3. Mexico
- 9.3. South America
- 9.3.1. Brazil
- 9.3.2. Argentina
- 9.3.3. Others
- 9.4. Europe
- 9.4.1. Germany
- 9.4.2. France
- 9.4.3. United Kingdom
- 9.4.4. Spain
- 9.4.5. Others
- 9.5. Middle East and Africa
- 9.5.1. Saudi Arabia
- 9.5.2. UAE
- 9.5.3. Others
- 9.6. Asia Pacific
- 9.6.1. China
- 9.6.2. Japan
- 9.6.3. South Korea
- 9.6.4. India
- 9.6.5. Thailand
- 9.6.6. Taiwan
- 9.6.7. Others
- 10. COMPETITIVE ENVIRONMENT AND ANALYSIS
- 10.1. Major Players and Strategy Analysis
- 10.2. Market Share Analysis
- 10.3. Mergers, Acquisitions, Agreements, and Collaborations
- 10.4. Vendor Competitiveness Matrix
- 11. COMPANY PROFILES
- 11.1. Eli Lilly and Company
- 11.2. AbbVie, Inc.
- 11.3. Novartis AG
- 11.4. Bristol Myers Squibb
- 11.5. F.Hoffmann-La Roche Ltd.
- 11.6. Johnson & Johnson Services, Inc.
- 11.7. Amgen Inc.
- 11.8. Merck & Co. Inc.
- 11.9. AstraZeneca PLC
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
